# MRD Response-adapted Allo-HSCT for Adverse-risk AML

> **NCT06301425** · NA · RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 178 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **OTHER:** Intervention group
- **OTHER:** Control group

## Key facts

- **NCT ID:** NCT06301425
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-24
- **Primary completion:** 2027-05-01
- **Final completion:** 2028-05-01
- **Target enrollment:** 178 (ESTIMATED)
- **Last updated:** 2024-07-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06301425

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06301425, "MRD Response-adapted Allo-HSCT for Adverse-risk AML". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06301425. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*